

Artificial Intelligence and Medical Devices: Opportunities and Challenges from a regulatory perspective

Folker Spitzenberger, PhD, M.D.R.A.

Department of Applied Natural Sciences

Centre for Regulatory Affairs in Biomedical Sciences

Technische Hochschule Lübeck University of Applied Sciences

Fraunhofer Einrichtung für Individualisierte und zellbasierte Medizintechnik - IMTE


27th DGRA Annual Congress, May 8th - 9th, 2025 in Bonn

AGENDA

- Examples of AI applications for medical devices
- Opportunities and challenges
 - NLF regulatory approach
 - Definitions
 - Risk categorization/classification
 - Conformity assessment procedure
 - Interfaces: QMS, RMS & TD
 - Change management
 - Standardization in the field of AI
- “Take Home”


Examples of AI applications ...

„What is the current and future significance of AI technology for the development, production and/or use of IVD products in your organization?“



Source: Bajorat et al. 2021: KI-basierte In-vitro-Diagnostika vor dem Hintergrund der IVDR und dem europäischen KI-Konzept; MPJ – Medizinproduktejournal, 28. Jahrgang, Heft 4, 2021

Examples of AI applications ...




Source: Mundorf & Ludwig 2024: Künstliche Intelligenz im medizinischen Labor: KI – aktueller Stand und Zukunftsperspektiven; Trillium Diagnostik, TD Heft 1/2024; DOI: <https://doi.org/10.47184/td.2024.01.08>


Examples of AI applications ...

Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices

[f Share](#) [X Post](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)



August 7, 2024 update: The U.S. Food and Administration updated the list of Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. With this update, the FDA has authorized 950 AI/ML-enabled medical devices.



07/16/2024	K240944	Swoop® Portable MR Imaging® System	Hyperfine, Inc.	Radiology	LNH
07/15/2024	K240285	Huxley SANSa Home Sleep Apnea Test (1000-00)	Huxley Medical	Anesthesiology	MNR
07/12/2024	K234009	Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)	Mighty Oak Medical	Radiology	QIH


Showing 1 to 50 of 1,016 entries

Previous **1** 2 3 4 5 ... 21 Next

Source: FDA Database


Source: <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices>

Examples of AI applications ...



[Source: U.S. FDA – Database of Approved Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices in the USA (Current as of 25.03.2025)]

Examples of AI applications ...






RADIOLOGY. Health AI Register


Products Companies News About ▾ Contact

Products

Find the artificial intelligence based software for radiology that you are looking for.
All products listed are available for the European market (CE marked).

Subspecialty: Modality: CE  : CE class  : FDA class  : Sort by:

All ▾ All ▾ MDR ▾ All ▾ All ▾ last modified ▾



Search...  121/232 results

Carebot

Carebot AI CXR


Radiologic abnormal finding detection, textual report generation, worklist prioritisation

Carebot AI CXR is a deep learning-based decision support software that assists radiologists in interpreting chest X-ray images in AP/PA projection. It serves as a secondary reader of seven key ...

CE: Class IIa - MDR 
FDA: 

<https://healthairegister.com/products/>

NLF regulatory approach



Timeline of AI strategic documents, effective as of April 2020, Source: "UNICRI :: United Nations Interregional Crime and Justice Research Institute". www.unicri.it , 10-09-2021

Prof. Dr. Folker Spitzengerger

NLF regulatory approach




Timeline of AI strategic documents, effective as of April 2020, Source: "UNICRI :: United Nations Interregional Crime and Justice Research Institute". www.unicri.it, 10-09-2021

Prof. Dr. Folker Spitzengerger



NLF regulatory approach

 Official Journal
of the European Union

EN
L series

2024/168912.7.2024

REGULATION (EU) 2024/1689 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 13 June 2024

laying down harmonised rules on artificial intelligence and amending Regulations (EC) No 300/2008,
(EU) No 167/2013, (EU) No 168/2013, (EU) 2018/858, (EU) 2018/1139 and (EU) 2019/2144 and
Directives 2014/90/EU, (EU) 2016/797 and (EU) 2020/1828 (Artificial Intelligence Act)

CHAPTER I GENERAL PROVISIONS

Article 1 Subject matter`

1. The purpose of this Regulation is to improve the functioning of the internal market and promote the uptake of human-centric and trustworthy artificial intelligence (AI), while ensuring a high level of protection of health, safety, fundamental rights enshrined in the Charter, including democracy, the rule of law and environmental protection, against the harmful effects of AI systems in the Union and supporting innovation.

CHAPTER I GENERAL PROVISIONS

... However, a fundamental revision of those Directives is needed to establish a robust, transparent, predictable and sustainable **regulatory framework for medical devices** which **ensures a high level of safety and health whilst supporting innovation**.

This Regulation aims to ensure the **smooth functioning of the internal market** as regards medical devices, taking as a base a **high level of protection of health for patients and users**, At the same time, this Regulation sets **high standards of quality and safety for medical devices** in order to meet common safety concerns as regards such products. ...

Excerpt from the **Recitals No. 1 and 2** of the **Regulation (EU) 2017/745** of the European Parliament and of the Council on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC



Option 3+: Horizontal EU legislative instrument following a proportionate **risk-based approach plus codes of conduct for non-high-risk AI systems**:

“A **regulatory framework for high-risk AI systems only**, with **the possibility for all providers of non-high-risk AI systems to follow a code of conduct**. The requirements will concern data, documentation and traceability, provision of information and transparency, human oversight and robustness and accuracy and would be mandatory for high-risk AI systems. Companies that introduced codes of conduct for other AI systems would do so voluntarily.”

“**AI systems** intended to be used as safety components of products that are **regulated under the New Legislative Framework legislation** (e.g. machinery, toys, medical devices, etc.) will **be subject to the same ex-ante and ex-post compliance and enforcement mechanisms** of the products of which they are a component. The key difference is that the ex-ante and ex-post mechanisms will ensure compliance **not only with the requirements established by sectorial legislation, but also with the requirements established by this regulation.**”

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL LAYING DOWN HARMONISED RULES ON ARTIFICIAL INTELLIGENCE (ARTIFICIAL INTELLIGENCE ACT) AND AMENDING CERTAIN UNION LEGISLATIVE ACTS, 2021/0106 (COD)



Option 3+: **Horizontal EU legislative instrument** following a proportionate **risk-based**




The CE marking indicates the conformity of the product with the Union legislation applying to the product and providing for CE marking. — The CE marking is affixed on products that will be placed on the EEA and Turkish market.

under the New Legislative Framework legislation (e.g. machinery, toys, medical devices, etc.) will **be subject to the same ex-ante and ex-post compliance and enforcement mechanisms** of the products of which they are a component. The key difference is that the ex-ante and ex-post mechanisms will ensure compliance **not only with the requirements established by sectorial legislation, but also with the requirements established by this regulation.**”

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL LAYING DOWN HARMONISED RULES ON ARTIFICIAL INTELLIGENCE (ARTIFICIAL INTELLIGENCE ACT) AND AMENDING CERTAIN UNION LEGISLATIVE ACTS, 2021/0106 (COD)

Definition „AI system“ (Art. 3 (1), AI Act)

(1) **‘AI system’** means (2) a machine-based system that is designed to operate with varying levels of autonomy and that (3) may exhibit adaptiveness after deployment, and that, for explicit or implicit objectives, (4) infers, from the input it receives, how to generate outputs such as predictions, content, recommendations, or decisions (5) that (6) can influence physical or virtual environments; (7)



<https://digital-strategy.ec.europa.eu/en/library/commission-publishes-guidelines-ai-system-definition-facilitate-first-ai-acts-rules-application>

Definitions

Definition „safety component“ (Art. 3 (14), AI Act)

‘safety component’ means a component of a product or of an AI system which fulfils a safety function for that product or AI system, or the failure or malfunctioning of which endangers the health and safety of persons or property;

Definition „substantial modification“ (Art. 3 (23), AI Act)

‘substantial modification’ means a change to an AI system after its placing on the market or putting into service which is not foreseen or planned in the initial conformity assessment carried out by the provider and as a result of which the compliance of the AI system with the requirements set out in Chapter III, Section 2 is affected or results in a modification to the intended purpose for which the AI system has been assessed;



AI Act – Risk categorization


(1) ... that **AI system shall be considered to be high-risk** where both of the following conditions are fulfilled:

(a) the **AI system is intended to be used as a safety component of a product, or the AI system is itself a product, covered by the Union harmonisation legislation listed in Annex I;**

(b) the **product** whose safety component pursuant to point (a) is the AI system, or the AI system itself as a product, **is required to undergo a third-party conformity assessment**, with a view to the placing on the market or the putting into service of that product pursuant to the Union harmonisation legislation listed in Annex I. ...

(2) **AI systems referred to in Annex III shall be considered to be high-risk ...**

AI Act, Article 6 (1), (2), in extracts



Source: <https://digital-strategy.ec.europa.eu/en/policies/regulatory-framework-ai>




AI Act – Risk categorization

ANNEX I

List of Union harmonisation legislation


Section A. List of Union harmonisation legislation based on the New Legislative Framework

1. Directive 2006/42/EC of the European Parliament and of the Council of 17 May 2006 on machinery, and amending Directive 95/16/EC (OJ L 157, 9.6.2006, p. 24);
2. Directive 2009/48/EC of the European Parliament and of the Council of 18 June 2009 on the safety of toys (OJ L 170, 30.6.2009, p. 1);
3. Directive 2013/53/EU of the European Parliament and of the Council of 20 November 2013 on recreational craft and personal watercraft and repealing Directive 94/25/EC (OJ L 354, 28.12.2013, p. 90);
4. Directive 2014/33/EU of the European Parliament and of the Council of 26 February 2014 on the harmonisation of the laws of the Member States relating to lifts and safety components for lifts (OJ L 96, 29.3.2014, p. 251);
5. Directive 2014/34/EU of the European Parliament and of the Council of 26 February 2014 on the harmonisation of the laws of the Member States relating to equipment and protective systems intended for use in potentially explosive atmospheres (OJ L 96, 29.3.2014, p. 309);
6. Directive 2014/53/EU of the European Parliament and of the Council of 16 April 2014 on the harmonisation of the laws of the Member States relating to the making available on the market of radio equipment and repealing Directive 1999/5/EC (OJ L 153, 22.5.2014, p. 62);
7. Directive 2014/68/EU of the European Parliament and of the Council of 15 May 2014 on the harmonisation of the laws of the Member States relating to the making available on the market of pressure equipment (OJ L 189, 27.6.2014, p. 164);
8. Regulation (EU) 2016/424 of the European Parliament and of the Council of 9 March 2016 on cableway installations and repealing Directive 2000/9/EC (OJ L 81, 31.3.2016, p. 1);
9. Regulation (EU) 2016/425 of the European Parliament and of the Council of 9 March 2016 on personal protective equipment and repealing Council Directive 89/686/EEC (OJ L 81, 31.3.2016, p. 51);
10. Regulation (EU) 2016/426 of the European Parliament and of the Council of 9 March 2016 on appliances burning gaseous fuels and repealing Directive 2009/142/EC (OJ L 81, 31.3.2016, p. 99);
11. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1);
12. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on *in vitro* diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176).






AI Act – Risk categorization




Source: WHO Global Model Regulatory Framework for Medical Devices including IVD Medical Devices (May 2017)




Source: <https://digital-strategy.ec.europa.eu/en/policies/regulatory-framework-ai>



AI Act – Risk categorization



Source: WHO Global Model Regulatory Framework for Medical Devices including IVD Medical Devices (May 2017)



Source: <https://digital-strategy.ec.europa.eu/en/policies/regulatory-framework-ai>


“The classification of an AI system as high-risk pursuant to this Regulation should not necessarily mean that the product whose safety component is the AI system, or the AI system itself as a product, is considered to be high-risk under the criteria established in the relevant Union harmonisation legislation that applies to the product. This is, in particular, the case for Regulations (EU) 2017/745 and (EU) 2017/746, where a third-party conformity assessment is provided for medium-risk and high-risk products.”

Recital 51, AI Act



Conformity assessment procedure (Art. 43)


Basic elements of conformity assessment leading to **CE marking**






Conformity assessment procedure (Art. 43)


Additional elements of conformity assessment leading to **CE marking**





(2) ... In **ensuring the compliance of high-risk AI systems** referred to in paragraph 1 with the requirements set out in this Section, and in order to **ensure consistency, avoid duplication and minimise additional burdens, providers shall have a choice of integrating**, as appropriate, the necessary **testing and reporting processes, information and documentation** they provide with regard to their product **into documentation and procedures that already exist and are required under the Union harmonisation legislation listed in Section A of Annex I.**


Interfaces: QMS, RMS & TD



Source: **Aykurt et al:** KI-basierte (IVD-)Medizinprodukte – Neue gesetzliche Anforderungen an das Qualitäts- und Risikomanagement im Zusammenspiel der MDR/IVDR und des EU AI Acts; in: Rethinking Quality – Wandel des Qualitätsmanagements durch Digitalisierung und Künstliche Intelligenz; Bericht zur GQW-Jahrestagung 2024 in Berlin, Springer Vieweg Verlag


Comparison of the requirements for the quality management system, risk management system and technical documentation according to MDR and AIA

QMS [MDR, Art. 10 vs. AIA, Art. 17] -
Comparison of 20 elements




■ No consent ■ Partial consent ■ Overall consent

RMS [MDR, Annex I, 2. - 5., 8. vs. AIA, Art. 9] -
Comparison of 25 elements



■ No consent ■ Partial consent ■ Overall consent

TD [MDR, Annex II, III vs. AIA, Annex IV] -
Comparison of 65 elements



■ No consent ■ Partial consent ■ Overall consent

Rules-Based AI Systems	Data-Driven/Machine-Learning AI Systems	
<ul style="list-style-type: none"> • Mimic human behavior-making decisions by applying static rules to arrive at predictable decisions. 	Locked Machine Learning Models	Continuous Learning/Adaptive Models
<ul style="list-style-type: none"> • Often visualized as a decision tree. 	<ul style="list-style-type: none"> • Neither the internal algorithms nor system outputs change automatically. 	<ul style="list-style-type: none"> • Utilize newly received data to test assumptions that underlie their operation in real-world use.
<ul style="list-style-type: none"> • May be originally developed based on a set of rules provided by human experts or can be based on training data. 	<ul style="list-style-type: none"> • Further machine learning can be implemented through external approval, or in a stepwise manner. 	<ul style="list-style-type: none"> • Programed to automatically modify internal algorithms and update external outputs in response to improvements being identified.
<ul style="list-style-type: none"> • The logic used to make decisions is usually clear and reproducible. 		

Source: AAMI/BSI - Machine Learning AI in Medical Devices: Adapting Regulatory Frameworks and Standards to Ensure Safety and Performance (2020)

Article 3 (23):

‘substantial modification’ means a **change to an AI system after its placing on the market** or putting into service **which is not foreseen or planned in the initial conformity assessment** carried out by the provider and as a result of which the **compliance of the AI system** with the requirements set out in Chapter III, Section 2 **is affected or results in a modification to the intended purpose** for which the AI system has been assessed;

Article 43 (4):

High-risk AI systems that have already been subject to a conformity assessment procedure **shall undergo a new conformity assessment procedure in the event of a substantial modification**

For **high-risk AI systems that continue to learn** after being placed on the market or put into service, **changes** to the high-risk AI system and its performance **that have been pre-determined by the provider at the moment of the initial conformity assessment** and are part of the information contained in the technical documentation referred to in point 2(f) of Annex IV, **shall not constitute a substantial modification**.

?

If a change in the intended purpose of an AI system was defined and

?

If a change in the intended purpose of an AI system was defined and foreseen in advance at the time of the original conformity assessment, is

High-risk AI system
procedure shall undergo
substantial modification
For high-risk AI system
put into service, changes to the high-risk AI system and its performance that have
been pre-determined by the provider at the moment of the initial conformity
assessment and are part of the information contained in the technical documentation
referred to in point 2(f) of Annex IV, shall not constitute a substantial modification.

?

Contains Nonbinding Recommendations

Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions

Guidance for Industry and Food and Drug Administration Staff

Document issued on December 4, 2024.

The draft of this document was issued on April 3, 2023.

For questions about this document regarding CDRH-regulated devices, contact the Digital Health Center of Excellence by email at digitalhealth@fda.hhs.gov. For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010, or by email at ocod@fda.hhs.gov. For questions about this document regarding CDER-regulated products, contact the Center for Drug Evaluation and Research at 301-796-8936 or by email at druginfo@fda.hhs.gov. For questions about this document regarding combination products, contact the Office of Combination Products by email at combination@fda.gov.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research
Office of Combination Products in the Office of the Commissioner



Final Document

IMDRF/AIML WG/N88 FINAL: 2025


Good machine learning practice for medical device development: Guiding principles

AUTHORING GROUP

Artificial Intelligence/Machine Learning-enabled Working
Group

27 January 2025


Standardization in the field of AI



ANNEX I	
List of new European Standards and European standardisation deliverables to be drafted	
Reference information	
1.	European standard(s) and/or European standardisation deliverable(s) on risk management systems for AI systems
2.	European standard(s) and/or European standardisation deliverable(s) on governance and quality of datasets used to build AI systems
3.	European standard(s) and/or European standardisation deliverable(s) on record keeping through logging capabilities by AI systems
4.	European standard(s) and/or European standardisation deliverable(s) on transparency and information provisions for users of AI systems
5.	European standard(s) and/or European standardisation deliverable(s) on human oversight of AI systems
6.	European standard(s) and/or European standardisation deliverable(s) on accuracy specifications for AI systems
7.	European standard(s) and/or European standardisation deliverable(s) on robustness specifications for AI systems
8.	European standard(s) and/or European standardisation deliverable(s) on cybersecurity specifications for AI systems
9.	European standard(s) and/or European standardisation deliverable(s) on quality management systems for providers of AI systems, including post-market monitoring processes
10.	European standard(s) and/or European standardisation deliverable(s) on conformity assessment for AI systems

Source: Standardisation request to the European Standardisation Organisations in support of Union policy on artificial intelligence (22.05.2023; C(2023) 3215 final)

Standardization in the field of AI




https://ai-watch.ec.europa.eu/topics/ai-standards_en



<https://publications.jrc.ec.europa.eu/repository/handle/JRC139430>

Standardization in the field of AI




JRC Technical Report

Analysis of the preliminary AI standardisation work plan in support of the AI Act

Soler Garrido, Josep
Fano Yela, Della
Panigutti, Cecilia
Junklewitz, Henrik
Harron, Ronan
Evas, Tatjana
André, Antoine-Alexandre
Scalzo, Salvatore

2023



JRC 139430

Table 1 Standards considered for harmonization by CEN-CENELEC JTC21 WG1, as presented in the plenary meeting on 16/17 January 2023

ISO/IEC 22989	Artificial Intelligence concepts and terminology
ISO/IEC 23053	Framework for Artificial Intelligence (AI) system using Machine Learning
ISO/IEC 42001	AI management system
ISO/IEC 23894	AI Risk Management
ISO/IEC 5259-part 1	Data quality for analytics and machine learning (ML) - Overview, terminology, and examples
ISO/IEC 5259-part 2	Data quality for analytics and machine learning (ML) Data quality measures
ISO/IEC 5259-part 3	Data quality for analytics and machine learning (ML) Data quality management requirements and guidelines
ISO/IEC 5259-part 4	Data quality for analytics and machine learning (ML) Data quality process framework
ISO/IEC 27001:2013	Information security management systems
ISO/IEC 42006	Requirements on bodies performing audit and certification of AI management systems
CEN-CENELEC Risk	AI Risk catalogue and management
CEN-CENELEC Trustworthiness	AI trustworthiness characterisation

European AI Act


ation organisations, led
, are in the process of
ssary AI standards,
t from the European

s some of the key
ected from upcoming
support the implemen-

handle/JRC139430


https://ai-watch.ec.europa.eu/topics/ai-standards_en

Standardization in the field of AI



„... ISO/IEC 22989 [3] and ISO/IEC 23894 [5] provide general guidance on AI concepts, terminology and *risk management*, but they do not specifically address the application of AI to *medical devices*. It must be noted that “risk” is defined in these documents as the effect of uncertainties on objectives (see also ISO 31000 [2]). This definition is useful for organizational or business *risk management*. The term “risk” used in the healthcare sector is different and is defined in ISO 14971:2019 as the combination of the probability of occurrence of *harm* and the *severity* of that *harm*. ...”

Standardization in the field of AI



IEC International Electrotechnical Commission

Standards development | Conformity assessment | Where we make a difference | Who benefits | News & resources | Programmes & initiatives | Who we are

Home / Standards development / Technical committees and subcommittees / TC 62 / ahG 9

TC 62 Medical equipment, software, and systems

Scope | Structure | Projects / Publications | Documents | Votes | Meetings | Collaboration Platform

Subgroups > **ahG 9**

ahG 9 Members

Convenor	National Committee
Mr Christian Kaestner	SE
Member	National Committee
Mr Eljar Amini-Nejad	DE
Mrs Giulia Arico	BE
Mr Ozan Aykurt	DE
Ms Karen Brown	CA
Mrs Caterina Brusasco	BE
Mr Jonas A. Bundgaard	DK

Title & Task

ahG 9

Alignment regarding TR 18988

The task of the group is to find consensus regarding the understanding of AI related terms and concepts (e.g. ISO/IEC 22989-2) in IEC TC 62. The group will offer the results to ISO/IEC JTC 1/SC 42/JWG 3 as input to their projects. However, the group might also choose to propose in addition a new work item proposal to make the results accessible to IEC TC 62's stakeholders.

These contributions are intended to support the Liaison Representative in representing the view of TC 62 and its SCs related to the differences between AI in medicine, as an aspect of healthcare, and general AI.

Terms and Reporting:

The group shall exist for the duration of the assigned projects ISO TR 18988 and ISO 22989-2 or until an NWIP in IEC TC 62 is approved.

The group shall produce a report on its activities in time for each plenary meeting of IEC TC 62. Written comments submitted to ISO/IEC 215 shall be sent in CC to the secretariat of IEC TC 62.

https://www.iec.ch/dyn/www/f?p=103:14:511274898739289:::FSP_ORG_ID,FSP_LANG_ID:49125,25



DIN Normen & Standards | Forschung & Innovation | DIN & seine Partner | Mitwirken | Service für Anwender*innen

Mitwirken > Normenausschüsse > NAGESUTECH

NA 176

DIN-Normenausschuss Gesundheitstechnologien (NAGesutech)

Über NAGesutech | Projekte | Entwürfe | Veröffentlichungen | Ersatzlose Zurückziehungen | Nationale Gremien | Europäische Gremien | Internationale

NA 176-02-05 AA

KI in der Medizin und im Gesundheitswesen

Veröffentlichungen | Projekte

Entwicklungen von Normen und Praktiken zu Werkzeugen, Prozessen und Anwendungen Künstlicher Intelligenz in der Medizin und im Gesundheitswesen

IHR KONTAKT

DIN-Normenausschuss Gesundheitstechnologien (NAGesutech)
Frau M. Sc.
Ulrike Schröder

Am DIN-Platz, Burggrafenstr. 6
10787 Berlin

Tel.: +49 30 2601-2919
Fax: +49 30 2601-42919

[Zum Kontaktformular >](#)

<https://www.din.de/de/mitwirken/normenausschuesse/nagesutech/nationale-gremien/wdc-grem:din21:366738849>




Projekte von NA 176-02-05 AA

Dokumentnummer	Beginn	Titel	
ISO/IEC AWI 22989-2	2024-08-06	Artificial intelligence - Concepts and terminology - Part 2: Healthcare	Kontakt zu DIN >
ISO/IEC AWI TR 18988	2023-04-28	Artificial intelligence - Application of AI technologies in health informatics	Kontakt zu DIN >

<https://www.din.de/de/mitwirken/normenausschuesse/nagesutech/nationale-gremien/74630/wdc-grem:din21:366738849!search-grem-details?masking=true>

Activities of implementation





Official Journal
of the European Union

EN
L series

2025/454

10.3.2025

COMMISSION IMPLEMENTING REGULATION (EU) 2025/454

of 7 March 2025

laying down the rules for the application of Regulation (EU) 2024/1689 of the European Parliament and of the Council as regards the establishment of a scientific panel of independent experts in the field of artificial intelligence

(Text with EEA relevance)




Tasks in 2024-2025

See a timeline of all key tasks required by the EU AI Act in 2024 and 2025, with references to the sources.

[Tasks: AI Office](#)
[Tasks: EU Member States](#)

<https://artificialintelligenceact.eu/>

MDCG:

Interplay between the MDR¹ & IVDR² and the AIA³



Bearbeitungsstand: 04.12.2024 17:14

Referentenentwurf

des Bundesministeriums für Wirtschaft und Klimaschutz und des Bundesministeriums der Justiz

Entwurf eines Gesetzes zur Durchführung der Verordnung (EU) 2024/1689 des Europäischen Parlaments und des Rates vom 13. Juni 2024 zur Festlegung harmonisierter Vorschriften für künstliche Intelligenz und zur Änderung der Verordnungen (EG) Nr. 300/2008, (EU) Nr. 167/2013, (EU) Nr. 168/2013, (EU) 2018/858, (EU) 2018/1139 und (EU) 2019/2144 sowie der Richtlinien 2014/90/EU, (EU) 2016/797 und (EU) 2020/1828 (Verordnung über künstliche Intelligenz)

(Gesetz zur Durchführung der KI-Verordnung)

Gesetzentwurf

der Bundesregierung

Entwurf eines Gesetzes zur Verbesserung der Rahmenbedingungen für die Erprobung von Innovationen in Reallaboren und zur Förderung des regulatorischen Lernens

„Take home“: Opportunities / Challenges

Opportunities (+)	Challenges/Risks (-)
Promoting confidence to embrace human-centric AI-based solutions by all stakeholders	AI Act may bring too strict and non-flexible requirements that prevent from innovation in the IT sector
Supporting the continuity of access to safe products such as medical devices on the basis of the NLF conformity assessment regulatory approach	AI Act may still risk creating two- or even multiple-track systems, if unclear definitions and concepts are not resolved
Basic and horizontal elements of conformity assessment such as QMS, RMS, technical documentation etc. allow for integration of requirements from sectorial legislation, such as MDR/IVDR	Conflicting requirements must be resolved, for example with regard to risk management, quality management and change management concepts in different product sectors
AI Act includes the EU principle of presumption of conformity by application of harmonised standards	Lacking, unclear or non-appropriate standard requirements will delay the implementation process and will put the EU behind with regard to innovative products

Thank you.



Ozan Aykurt



Pauline Kaufmann



Folker Spitzenberger

Centre for Regulatory Affairs in Biomedical Sciences

Technische Hochschule Lübeck

Mönkhofer Weg 239

23562 Lübeck

Tel. +49 451 300 5372

E-Mail folker.spitzenberger@th-luebeck.de; folker.spitzenberger@imte.fraunhofer.de

Website www.th-luebeck.de